Technology | Breast Biopsy Systems | August 31, 2017

Hologic Announces Availability of Brevera Breast Biopsy System With CorLumina Imaging Technology

System offers real-time imaging of tissue samples, resulting in major cost and time savings

Hologic Announces Availability of Brevera Breast Biopsy System With CorLumina Imaging Technology

August 31, 2017 — Hologic Inc. announced U.S. commercial availability of the Brevera breast biopsy system with CorLumina imaging technology, a real-time breast biopsy and verification system. The system enhances workflow, improves the patient experience and streamlines the entire biopsy process from start to finish. It is designed to increase biopsy accuracy with real-time imaging that delivers valuable information at the point of care, enabling clinicians to make informed decisions with confidence.

The Brevera system is the world's first and only breast biopsy solution to combine tissue acquisition, real-time imaging, sample verification and advanced post-biopsy handling in one, integrated system, according to Hologic. Designed for 2-D and 3-D breast biopsy, the system allows physicians to perform fast and efficient procedures that save costs and improve the patient experience.1 

Until now, radiologists performing stereotactic breast biopsy procedures to diagnose breast cancer were often required to leave the patient under compression while they moved to another room to image and verify tissue samples. This leads to lengthy procedure times and anxious, uncomfortable patients, and can interrupt facility screening schedules. With the Brevera system, radiologists are able to obtain and image tissue samples in the procedure room in just a few seconds, potentially saving up to 10 minutes per patient and cutting the procedure time by up to 25 percent.2

In addition to saving facility resources and physician time during a breast biopsy procedure, the Brevera system's proprietary CorLumina imaging technology helps enhance workflow across multiple departments within a health system. The system automates the tissue sample collection and separation process, which allows patient tissue to be sent to pathology with little or no manual handling and protects the integrity of samples. The system also features picture archiving and communication system (PACS) integration for advanced image sharing and transfer of patient records.

The Brevera system is designed for use with Hologic's Affirm prone biopsy system, Affirm breast biopsy guidance system and MultiCare Platinum system, as well as most upright and prone systems on the market.

For more information: www.hologic.com

 

References

1. 3-D biopsy only when used with the Affirm breast biopsy system. 
2. 2015 Kadence International survey of 200 healthcare professionals.

Related Content

Medical researchers at Flinders University have established a new link between high body mass index (BMI) and breast cancer survival rates — with clinical data revealing worse outcomes for early breast cancer (EBC) patients and improved survival rates in advanced breast cancer (ABC).

Getty Images

News | Women's Health | May 13, 2021
May 13, 2021 — Medical researchers at Flinders University
News | Artificial Intelligence | May 11, 2021
May 11, 2021 — Whiterabbit, an AI technology company focused on early...
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane